Open AccessFOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
Author(s) -
In Rae Cho,
Hyun Seung Kang,
Jung Hyun Jo,
Hee-Seung Lee,
Moon Jae Chung,
Jeong Youp Park,
Seung Woo Park,
Si Young Song,
Chansik An,
MiSuk Park,
Seungmin Bang
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i2.182
Subject(s) - folfirinox , medicine , gemcitabine , pancreatic cancer , regimen , adverse effect , oncology , neutropenia , cohort , population , cancer , chemotherapy , irinotecan , colorectal cancer , environmental health
FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem + nabPTX) were recently introduced for metastatic pancreatic cancer treatment. However, studies that compared these two regimens and studies in Asian populations are lacking.